Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

Seagen Inc SGEN and Astellas Pharma Inc ALPMF announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (enfortumab vedotin-ejfv) in muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. 

  • Data will be presented at the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU).
  • The preliminary analysis of 22 patients showed 36.4% had a pathologic complete response, the primary endpoint, displaying no signs of cancer upon microscopic examination of tissue cells removed during surgery. 
  • Also See: Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer.
  • Half (50%) of all patients had a pathological downstaging, or reduction in tumor size, a secondary endpoint of the trial. 
  • All patients underwent surgery, and no surgeries were delayed following treatment with enfortumab vedotin. 
  • "The initial findings from EV-103 Cohort H are encouraging, and we look forward to learning more from the Phase 3 studies evaluating enfortumab vedotin in muscle-invasive bladder cancer in combination with the anti-PD-1 therapy pembrolizumab," said Marjorie Green, SVP and Head of Late-Stage Development, Seagen.
  • Price Action: SGEN shares closed at $124.51 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralbladder cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!